0.425
Schlusskurs vom Vortag:
$0.384
Offen:
$0.385
24-Stunden-Volumen:
7.05M
Relative Volume:
0.29
Marktkapitalisierung:
$21.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.89M
KGV:
-0.168
EPS:
-2.53
Netto-Cashflow:
$-11.95M
1W Leistung:
+34.07%
1M Leistung:
+119.07%
6M Leistung:
-65.16%
1J Leistung:
-75.71%
Plus Therapeutics Inc Stock (PSTV) Company Profile
Firmenname
Plus Therapeutics Inc
Sektor
Branche
Telefon
737.255.7194
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Vergleichen Sie PSTV mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PSTV
Plus Therapeutics Inc
|
0.425 | 16.17M | 0 | -12.89M | -11.95M | -2.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
2020-10-16 | Eingeleitet | Maxim Group | Buy |
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
What analysts say about Plus Therapeutics Inc. stockSignificant capital appreciation - Autocar Professional
Plus Therapeutics Inc. Stock Analysis and ForecastBreakthrough stock performance - jammulinksnews.com
Is Plus Therapeutics Inc. a good long term investmentBreakout profit opportunities - jammulinksnews.com
What drives Plus Therapeutics Inc. stock priceOutstanding yields - jammulinksnews.com
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases | PSTV Stock News - GuruFocus
Plus Therapeutics Announces Clinical Trial Presentation and Educational Symposium at 2025 SNO/ASCO CNS Metastases Conference - Nasdaq
Plus Therapeutics Presents ReSPECT-LM Clinical Trial - GlobeNewswire
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases - TradingView
Plus Therapeutics Advances Pediatric Brain Tumor Treatment with New Clinical Study - TipRanks
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference - GlobeNewswire
Plus Therapeutics Announces Two CNSide Presentations at the Upco - GuruFocus
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference | PSTV Stock News - GuruFocus
Plus Therapeutics' CNSide Showcases Innovative CSF Assay Data at SNO/ASCO CNS Metastases Conference 2025 - Nasdaq
Revolutionary CNS Cancer Detection: Plus Therapeutics Unveils Game-Changing Clinical Data at Major Conference - Stock Titan
Plus Therapeutics Soars 10.51% on Promising Clinical Trial Results - AInvest
Plus Therapeutics begins treatment in REYOBIQ dose optimization trial By Investing.com - Investing.com South Africa
Plus Therapeutics Announces Initial Patients Successfully - GlobeNewswire
Plus Therapeutics begins treatment in REYOBIQ dose optimization trial - Investing.com
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases | PSTV Stock News - GuruFocus
Plus Therapeutics announces initial patients successfully treated in ReSPECT-LM dose optimization trial for Reyobiq™ in leptomeningeal metastases - MarketScreener
Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment - Nasdaq
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times
Breakthrough Brain Cancer Drug REYOBIQ Achieves 80% Tumor Reduction in Phase 1 Trial, Advances to Next Stage - Stock Titan
Plus Therapeutics shares fall 3.72% premarket after FDA clearance of Reyobiq for childhood brain cancer. - AInvest
Plus Therapeutics, Inc. shares fall 1.63% premarket after Novartis' Cosentyx fails in Phase III GCAptAIN study. - AInvest
Stock under $1with a very strong catalyst to buy and hold for a minimum of three years - AInvest
Plus Therapeutics Advances Brain Cancer Treatment: FDA Green Light and $17.6M Boost for Critical Trial - Stock Titan
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM - GuruFocus
PSTV SEC FilingsPlus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright Adjusts Price Target for Plus Therapeutics (PSTV) | PSTV Stock News - GuruFocus
Plus Therapeutics Soars 25.71% on FDA Trial Approval - AInvest
Plus Therapeutics (PSTV) Shares Surge After FDA Trial Clearance - GuruFocus
PSTV Stock Update: D. Boral Capital Maintains Hold Rating for Plus Therapeutics | PSTV Stock News - GuruFocus
Plus Therapeutics Announces Restructuring Of Its Equity Financing - Nasdaq
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN
Plus (PSTV) Upgraded to Buy: Here's Why - Nasdaq
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Plus Therapeutics (PSTV) Sees Stock Dip Amid New Share Sale Fili - GuruFocus
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering (PSTV:NASDAQ) - Seeking Alpha
Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | P - GuruFocus
Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | PSTV Stock News - GuruFocus
Plus Therapeutics Modifies Security Holders’ Rights - TipRanks
Plus Therapeutics Plunges 10.89% Amid Institutional Shifts - AInvest
Leptomeningeal Metastases Pipeline 2025: MOA, ROA, - openPR.com
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials - AlphaStreet
Plus Therapeutics Appeals Nasdaq Delisting Decision - TipRanks
Plus Therapeutics (NASDAQ:PSTV) Given New $20.50 Price Target at Ascendiant Capital Markets - Defense World
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - mx.advfn.com
Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):